TITLE:
Study Evaluating rhIL-11 in Active Crohn's Disease

CONDITION:
Crohn Disease

INTERVENTION:
Recombinant Human Interleukin-11 (rhIL-11)

SUMMARY:

      The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in
      patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from
      220-400).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Documented, signed and dated informed consent to participate in this trial prior to
             any study related procedures being performed.

          -  Men and women age 16 years and over.

          -  Diagnosis of Crohn's disease for at least 6 months that has been appropriately
             documented and confirmed by radiological studies, endoscopy (with histological
             examination preferred), or surgical pathology (Patients with a diagnosis of Crohn's
             disease for less than 6 months may be included if the diagnosis is confirmed by a
             biopsy characteristic of Crohn's disease)

        Exclusion Criteria:

        Use of the following medications within the specified time period prior to randomization:

          -  Nonsteroidal anti-inflammatory drugs (NSAIDs; including Cyclooxygenase-2 [COX-2]
             inhibitors and >500 mg/day acetylsalicylic acid)

          -  Codeine-containing compounds

          -  Corticosteroid enemas
      
